Global Artemisinin Combination Therapy Market Share

Statistics for the 2023 & 2024 Global Artemisinin Combination Therapy market share, created by Mordor Intelligence™ Industry Reports. Global Artemisinin Combination Therapy share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Global Artemisinin Combination Therapy Industry

The artemisinin combination therapy market is highly fragmented and consists of several major players. The major players on the international stage manufacture the majority of artemisinin combination therapy drugs. Market leaders with more funds for research and a better distribution system have established their positions in the market. Some of the global players are based in developed countries like the United States, the United Kingdom, France, Germany, and Japan. Some of the companies currently dominating the market are Cipla Inc., PLC, Novartis AG, Sanofi S.A., KPC Pharmaceuticals, and Shanghai Fosun Pharmaceutical Co., Ltd., among others.

Artemisinin Combination Therapy Market Leaders

  1. Novartis AG

  2. KPC Pharmaceuticals

  3. Cipla Ltd.

  4. Sanofi S.A.

  5. Fosun Pharmaceutical (Guilin Pharmaceutical)

*Disclaimer: Major Players sorted in no particular order

Artemisnin Combination Therapy Market Concentration.png

Artemisinin Combination Therapy Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)